Minerva Surgical to Present at the 41st Annual J.P. Morgan Healthcare Conference
Minerva Surgical, focused on women's health and treatment of Abnormal Uterine Bleeding (AUB), will present at the 41st Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Minerva Surgical, focused on women's health and treatment of Abnormal Uterine Bleeding (AUB), will present at the 41st Annual J.P. Morgan Healthcare Conference on January 12th at 9:45 a.m. PT. The event will be accessible via a live audio webcast on Minerva's website. The company offers minimally invasive alternatives to hysterectomy for AUB treatment, aiming to address common uterine health issues and avoid unnecessary surgeries.
Details
News Market Reaction – UTRS
The recorded move for UTRS in the trading session of this news was +10.91%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SANTA CLARA, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS) (Minerva Surgical or the Company), a women's health company focused on the treatment of Abnormal Uterine Bleeding (AUB), announced today that its management team will present at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12th at 9:45 a.m. Pacific Time.
A live audio webcast and replay of the presentation may be accessed through the “Recent Events” section of Minerva’s website at http://ir.minervasurgical.com.
About Minerva Surgical, Inc.
Minerva Surgical is a commercial-stage medical technology company focused on developing, manufacturing, and commercializing minimally invasive solutions to meet the distinct uterine healthcare needs of women. The Company has established a broad product line of commercially available, minimally invasive alternatives to hysterectomy, which are designed to address the most common causes of Abnormal Uterine Bleeding (AUB) in most uterine anatomies. The Minerva Surgical solutions can be used in a variety of medical treatment settings and aim to address the drawbacks associated with alternative treatment methods and to preserve the uterus by avoiding unnecessary hysterectomies.
MEDIA CONTACT
Mike Clapper
mike.clapper@minervasurgical.com
804-295-7676
INVESTOR RELATIONS CONTACT
Caroline Corner
investors@minervasurgical.com
415-202-5678
RELATED LINKS
https://www.minervasurgical.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.